Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Scientists thought they knew how this 70-year-old leukemia drug worked | ScienceDaily (opens in a new tab)

sciencedaily.com · 2026-09-24

Short answerEvidenceSource

Short answer

Mixed

Mixed.

One claim goes further than the study. One other point was not covered by the paper.

  • 2 supported
  • 1 overstated
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

One claim overstates the study. Two of four check out. One claim the study doesn't address.

  • 2 supported
  • 1 overstated
  • 1 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4OverstatedA team from CeMM, Oxford, the Weizmann Institute, and the University of Dundee identified NUDT5 as an unexpected factor in how cells respond to 6-TG.View evidenceHide evidence

Why this verdict

The paper profile supports that NUDT5 is involved in cellular response to 6-TG and that the study probes an unexpected/non-enzymatic role. But the claim that this team 'identified NUDT5 as an unexpected factor' overstates novelty relative to the profile, which says prior genome-wide CRISPR loss-of-function studies had already implicated NUDT5 as a mediator of 6-TG toxicity. The institutional affiliations are not assessable from the abstract profile.

1

Study evidence

Chemical degradation of NUDT5, combined with orthogonal CRISPR knockout and reconstitution, supports a non-enzymatic role for NUDT5 in modulating the cellular response to 6-thioguanine.

“These degraders, in conjunction with orthogonal CRISPR knock-out and reconstitution experiments, support a non-enzymatic role for NUDT5 in modulating the cellular response to 6-TG.”
Claim 2 of 4Not coveredScientists thought they knew how the 70-year-old leukemia drug 6-thioguanine (6-TG) worked, but the study suggests there is still a hidden mechanism affecting response to the drug.View evidenceHide evidence

As stated70-year-old

Why this verdict

The abstract-level profile supports the broad idea that the study uncovered an additional, non-enzymatic NUDT5-related mechanism modulating cellular response to 6-TG. However, the headline framing that scientists 'thought they knew' how the drug worked, and the '70-year-old leukemia drug' framing, are not verifiable from the supplied abstract profile. The headline therefore adds historical and epistemic color beyond what can be checked at this depth.

1

Study evidence

Chemical degradation of NUDT5, combined with orthogonal CRISPR knockout and reconstitution, supports a non-enzymatic role for NUDT5 in modulating the cellular response to 6-thioguanine.

“These degraders, in conjunction with orthogonal CRISPR knock-out and reconstitution experiments, support a non-enzymatic role for NUDT5 in modulating the cellular response to 6-TG.”
Claim 3 of 4SupportedBlocking NUDT5's enzymatic activity had little effect, but removing the protein protected cells from the toxic effects of 6-TG.View evidenceHide evidence

Why this verdict

The profile states that selective NUDT5 degraders were developed and used with CRISPR knockout/reconstitution experiments to dissociate catalytic inhibition from protein loss, supporting a non-enzymatic role for NUDT5 in modulating 6-TG response. This matches the story's core contrast between inhibiting NUDT5 enzymatic activity and removing/depleting the protein, though the abstract profile does not provide quantitative effect sizes or detailed assay conditions.

1

Study evidence

The authors developed and validated a selective, cell-active NUDT5-targeted protein degrader toolkit.

“we develop and validate a selective, cell-active NUDT5 degrader toolkit”
2

Study evidence

Chemical degradation of NUDT5, combined with orthogonal CRISPR knockout and reconstitution, supports a non-enzymatic role for NUDT5 in modulating the cellular response to 6-thioguanine.

“These degraders, in conjunction with orthogonal CRISPR knock-out and reconstitution experiments, support a non-enzymatic role for NUDT5 in modulating the cellular response to 6-TG.”
Claim 4 of 4SupportedThe researchers say NUDT5 influences thiopurine sensitivity through a non-catalytic role, and that it appears to have effects opposite to NUDT15, which is known to affect thiopurine response.View evidenceHide evidence

Why this verdict

The profile supports a non-catalytic/non-enzymatic role for NUDT5 in 6-TG response and reports that NUDT5 protein depletion is antagonistic to NUDT15 inhibition. The story's hedged phrasing that NUDT5 'appears' to have effects opposite to NUDT15 is consistent with the abstract-level statement of antagonism, although mechanistic and quantitative details are unavailable at this depth.

1

Study evidence

Chemical degradation of NUDT5, combined with orthogonal CRISPR knockout and reconstitution, supports a non-enzymatic role for NUDT5 in modulating the cellular response to 6-thioguanine.

“These degraders, in conjunction with orthogonal CRISPR knock-out and reconstitution experiments, support a non-enzymatic role for NUDT5 in modulating the cellular response to 6-TG.”
2

Study evidence

Depletion of NUDT5 protein is antagonistic to NUDT15 inhibition in shaping the cellular response to 6‑thioguanine.

“Depletion of NUDT5 protein is antagonistic to NUDT15 inhibition”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The paper develops and validates a selective, cell-active NUDT5-targeted protein degrader toolkit, including target engagement, ternary complex formation, degradation kinetics, and proteome-wide selectivity.

    The story mentions degradation/removal of NUDT5 but does not substantially cover the paper's central technical toolkit-development and validation contribution, including selectivity and degrader-mechanism characterization.

    From Degrader toolkit development and orthogonal validation

3 things the story did carry across
  • The biological conclusion relies on degraders used together with orthogonal CRISPR knockout and reconstitution experiments to support a non-enzymatic NUDT5 role in 6-TG response.
  • The paper reports antagonism between NUDT5 protein depletion and NUDT15 inhibition in shaping cellular response to 6-TG.
  • The evidence in the profile is cellular/in vitro basic research rather than direct patient-response or clinical-treatment evidence.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

in vitro

1Lead resultin vitroDevelop and validate a selective, cell-active NUDT5-targeted protein degrader toolkit, including evidence of target engagement, ternary complex formation, degradation kinetics, and proteome-wide selectivity.Degrader toolkit development and orthogonal validationExpand

In plain English

Paper reports development and validation of a selective, cell-active NUDT5-targeted protein degrader toolkit and orthogonal characterization of target engagement, ternary complex formation, degradation kinetics, and proteome-wide selectivity, and uses the degraders together with genetic perturbations to probe NUDT5 function in 6-TG response.

Key findings

  • The authors developed and validated a selective, cell-active NUDT5-targeted protein degrader toolkit.
  • Orthogonal characterization demonstrated target engagement, ternary complex formation, and measurable degradation kinetics for the NUDT5 degraders.
“we develop and validate a selective, cell-active NUDT5 degrader toolkit”
What this piece can’t prove
  • The abstract does not specify experimental conditions (cell lines, concentrations, time points), assay platforms, or statistical measures.

2 further details could not be confirmed from the summary.

2in vitroUse orthogonal genetic perturbation (CRISPR knockout and reconstitution) together with chemical degradation to show NUDT5 modulates cellular response to 6-thioguanine via a non-enzymatic (scaffolding/structural) role, dissociating catalytic inhibition from protein loss.Cellular CRISPR knockout and chemical degrader comparisonExpand

In plain English

Using a selective, cell-active NUDT5 degrader toolkit together with orthogonal CRISPR-Cas9 knockout and reconstitution experiments, the authors report that NUDT5 modulates cellular response to the antimetabolite 6-thioguanine (6-TG) via a non-enzymatic role, dissociating catalytic inhibition from protein loss. Depletion of NUDT5 protein is reported to be antagonistic to NUDT15 inhibition, indicating a distinct mode-of-action with potential therapeutic implications.

Key findings

  • Chemical degradation of NUDT5, combined with orthogonal CRISPR knockout and reconstitution, supports a non-enzymatic role for NUDT5 in modulating the cellular response to 6-thioguanine.
  • Depletion of NUDT5 protein is antagonistic to NUDT15 inhibition, indicating a distinct mode-of-action that dissociates catalytic inhibition from protein loss.
“These degraders, in conjunction with orthogonal CRISPR knock-out and reconstitution experiments, support a non-enzymatic role for NUDT5 in modulating the cellular response to 6-TG.”
What this piece can’t prove

2 further details could not be confirmed from the summary.

3in vitroDemonstrate pharmacologic interaction/epistasis between NUDT5 protein depletion and NUDT15 inhibition in shaping cellular response to 6-thioguanine, implying distinct modes of action with therapeutic implications.in vitro interaction study / degrader and genetic perturbation toolkitExpand

In plain English

The paper's abstract reports that depletion of NUDT5 protein is antagonistic to NUDT15 inhibition in determining cellular response to 6‑thioguanine (6‑TG), based on experiments using selective, cell‑active NUDT5 degraders together with orthogonal CRISPR knock-out/reconstitution. This is presented as evidence that NUDT5 has a non‑enzymatic role distinct from NUDT15 activity in modulating 6‑TG sensitivity.

Key findings

  • Depletion of NUDT5 protein is antagonistic to NUDT15 inhibition in shaping the cellular response to 6‑thioguanine.
“Depletion of NUDT5 protein is antagonistic to NUDT15 inhibition”
What this piece can’t prove
  • Summary is based solely on the abstract; experimental details (assay types, cell lines, doses, quantitative interaction metrics, and statistical analyses) are not provided.
  • Unclear whether the reported antagonism was observed across multiple models or is context‑specific.
  • Cannot confirm from abstract whether interaction analyses used formal synergy/antagonism models or descriptive comparisons.
Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 38 candidate papers

Candidate

Author response for "Lipstick structure revealed by multimodal strain- and time-dependent rheology"

2026 · Crossref

Source (opens in a new tab)

And 32 more candidates considered.